论文部分内容阅读
目的对不同临床分期、分化程度、淋巴转移及治疗前后乳腺癌患者血清及组织细胞生长因子(HGF)进行检测,分析其作用机制及其临床意义。方法选择2014年1月—2015年3月乳腺癌患者63例(观察组),良性肿瘤人群45例(对照组),正常人群40例(正常组)。检测不同程度乳腺组织HGF蛋白表达。结果观察组血清HGF浓度为(34.61±3.10)μg/L,高于对照组(10.23±1.94)μg/L和正常组(9.45±1.86)μg/L(P<0.05);观察组乳腺癌组织HGF阳性率为58.73%(37/63),高于对照组6.67%(3/45)和正常组2.50%(1/40)(P<0.05);治疗后血清HGF浓度为(17.80±2.93)μg/L,低于治疗前(P<0.05);Ⅲ期、低分化及淋巴转移患者血清及组织HGF均高于Ⅰ+Ⅱ期、中、高分化及未淋巴转移患者(P<0.05);治疗后乳腺癌组织HGF阳性率低于治疗前(P<0.05)。结论乳腺癌患者血清HGF浓度及乳腺组织HGF蛋白水平显著升高,且随着分期的增加、分化程度的降低及淋巴转移而增加,HGF与乳腺癌发生、发展及诱导细胞侵袭过程存在密切关系。
Objective To detect serum and tissue growth factor (HGF) in patients with breast cancer before and after different clinical stage, differentiation, lymph node metastasis and their clinical significance. Methods From January 2014 to March 2015, 63 breast cancer patients (observation group), 45 benign tumor patients (control group) and 40 normal subjects (normal group) were selected. Detect HGF protein expression in different degree of breast tissue. Results The serum concentration of HGF in the observation group was (34.61 ± 3.10) μg / L, higher than that in the control group (10.23 ± 1.94) μg / L and the normal group (9.45 ± 1.86) μg / L The positive rate of HGF was 58.73% (37/63), higher than 6.67% (3/45) in the control group and 2.50% (1/40) in the normal group (P <0.05). The serum HGF concentration was (17.80 ± 2.93) (P <0.05). The serum and tissue HGF levels in stage Ⅲ, poorly differentiated and lymphatic metastasis were higher than those in stage Ⅰ + Ⅱ, moderately differentiated and non - lymphatic metastatic lymph nodes (P <0.05). The positive rate of HGF in breast cancer tissues after treatment was lower than that before treatment (P <0.05). Conclusions Serum HGF concentration and HGF protein level in breast cancer patients are significantly increased, and with the increase of staging, differentiation and lymphatic metastasis, HGF is closely related to the occurrence and development of breast cancer and the induction of cell invasion.